Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="SALLES, G" or (type exact bookEditor and editor="SALLES, G")

Add to list
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

A Chanan-Khan, P Cramer, F Demirkan, G Fraser, RS Silva, S Grosicki, A Pristupa, A Janssens, J Mayer, NL Bartlett, et al.

(2016) LANCET ONCOLOGY. 17(2). p.200-211
Add to list
- Conference Paper
- C3
Pattern of infections observed during the maintenance phase in the PRIMA study

M Bouteloup, J Seymour, P Feugier, Fritz Offner (UGent) , A Lopez-Guillermo, R Bouabdallah, L Pedersen, P Brice, D Belada and G Salles

(2011) ANNALS OF ONCOLOGY. 22(suppl. 4). p.189-189
Add to list
- Conference Paper
- C3
Impact of induction chemotherapy regimen on response, safety and outcome in the PRIMA study

F Morschhauser, J Seymour, P Feugier, Fritz Offner (UGent) , A Lopez-Guillermo, R Bouabdallah, L Pedersen, P Brice, D Belada, L Xerri, et al.

(2011) ANNALS OF ONCOLOGY. 22(suppl. 4). p.89-89
Add to list
- Conference Paper
- C3
FCGR3A polymorphism does not significantly affect response and outcome of follicular lymphoma patients treated in the PRIMA study with rituximab and chemotherapy followed by rituximab maintenance or observation

H Ghesquieres, J Seymour, Fritz Offner (UGent) , P Feugier, P Brice, C Haioun, O Casasnovas, J Catalano, F Jardin, L Xerri, et al.

(2011) ANNALS OF ONCOLOGY. 22(suppl. 4). p.187-188
Add to list
- Conference Paper
- C3
Rituximab maintenance for 2-years significantly improves the outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy: results of the PRIMA study

G Salles, J Catalano, P Feugier, Fritz Offner (UGent) , R Bouabdallah, D Caballero, P Brice, LM Pedersen, C Haioun, D Belada, et al.

(2010) HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. 95(suppl. 2). p.229-229
Add to list
- Journal Article
- A1
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study

S CHOQUET, V LEBLOND, R HERBRECHT, G SOCIE, AM STOPPA, P VANDENBERGHE, A FISCHER, F MORSCHHAUSER, G SALLES, W FEREMANS, et al.

(2006) BLOOD. 107(8). p.3053-3057
Add to list
- Conference Paper
- C3
Efficacy and safety of Rituximab in B-cell post transplantation lymphoproliferative disorders (B-PTLD): Preliminary results of a multicenter, open label, phase II trial (M39037 TRIAL)

S CHOQUET, R HERBRECHT, G SOCIE, AM STOPPA, P VANDENBERGHE, W FEREMENS, A FISCHER, F MORSCHAUSER, G SALLES, E VILMER, et al.

(2002) BLOOD. 100(11).

Academic Bibliography

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

Pattern of infections observed during the maintenance phase in the PRIMA study

Impact of induction chemotherapy regimen on response, safety and outcome in the PRIMA study

FCGR3A polymorphism does not significantly affect response and outcome of follicular lymphoma patients treated in the PRIMA study with rituximab and chemotherapy followed by rituximab maintenance or observation

Rituximab maintenance for 2-years significantly improves the outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy: results of the PRIMA study

Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study

Efficacy and safety of Rituximab in B-cell post transplantation lymphoproliferative disorders (B-PTLD): Preliminary results of a multicenter, open label, phase II trial (M39037 TRIAL)

Contents

Support

Contact